Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Syndax Pharmaceuticals ( (SNDX) ).
On October 24, 2025, Syndax Pharmaceuticals announced that the FDA approved Revuforj® (revumenib) for treating relapsed or refractory acute myeloid leukemia (AML) with a susceptible NPM1 mutation in patients aged one year and older. This approval marks the first and only FDA-approved therapy for both R/R AML with an NPM1 mutation and R/R acute leukemia with a KMT2A translocation, solidifying Syndax’s leadership in menin inhibition. The approval is based on data from the AUGMENT-101 trial, which showed a 23% complete remission rate. Revuforj’s inclusion in the NCCN Guidelines and its availability through Syndax’s network of specialty distributors highlights its potential to become a new standard of care for these aggressive blood cancers.
The most recent analyst rating on (SNDX) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Syndax Pharmaceuticals stock, see the SNDX Stock Forecast page.
Spark’s Take on SNDX Stock
According to Spark, TipRanks’ AI Analyst, SNDX is a Neutral.
Syndax Pharmaceuticals faces significant risks due to declining revenues, persistent losses, and negative cash flows, which weigh heavily on its overall score. While the balance sheet remains strong with low leverage, the technical indicators suggest a bearish trend. The valuation is unattractive due to negative earnings. Despite these challenges, the recent earnings call provided some positive news with product launches and a strengthened financial position, partially offsetting the negative aspects. Overall, the company’s ability to improve financial performance and achieve market penetration in the face of competition will be crucial for future stock performance.
To see Spark’s full report on SNDX stock, click here.
More about Syndax Pharmaceuticals
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company focused on advancing innovative cancer therapies.
Average Trading Volume: 2,434,133
Technical Sentiment Signal: Hold
Current Market Cap: $1.3B
For a thorough assessment of SNDX stock, go to TipRanks’ Stock Analysis page.